Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Technetium-99m-labeled albumin microspheres are diagnostic nuclear medicine agents created by aggregating human serum albumin and labeling it with technetium-99m, a gamma-emitting radionuclide. When injected into systemic or organ-specific vasculature (such as hepatic or pulmonary arteries), these microspheres become localized within the microvasculature, where they emit gamma photons that can be detected by gamma cameras, enabling perfusion mapping and the assessment of vascular function. This agent is primarily used in diagnostic imaging procedures like lung perfusion scans, preoperative vascular mapping for surgery, planning for selective internal radiation therapy, and evaluation of tumor vasculature for radioembolization. They are not biological therapeutic targets, but rather marker particles for imaging, with safety concerns focused on non-target embolization and minimal radiation exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Technetium-99m-labeled albumin microsphere (Tc-99m-albumin microsphere).